ODTC — Odonate Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $54.84m
- -$40.18m
Annual income statement for Odonate, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 3.08 | 32.7 | 90.8 | 115 | 127 |
| Operating Profit | -3.08 | -32.7 | -90.8 | -115 | -127 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.08 | -32.7 | -89 | -112 | -126 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.08 | -32.7 | -89 | -112 | -126 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.08 | -32.7 | -89 | -112 | -126 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -3.08 | -32.7 | -89 | -112 | -126 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.65 | -48.7 | -145 | -162 | -154 |
| Dividends per Share |